Latest News and Press Releases

STOCKHOLM, Sweden, Nov. 30, 2005 (PRIMEZONE) -- Members of Meda's new executive management team bought a total of 1,625,000 warrants in Meda. This team was formed after the Viatris acquisition. Each...

-- 41,628,926 shares, corresponding to 99.61 percent of the offered shares, have been subscribed through exercise of subscription rights -- Including the shares that have been...

STOCKHOLM, Sweden, Nov. 7, 2005 (PRIMEZONE) -- Interim report, January -- September 2005: -- Group sales amounted to SEK 1614 million (570 million) -- Operating profit increased to SEK 361.3...

STOCKHOLM, Oct. 17, 2005 (PRIMEZONE) -- Today, Meda's extraordinary general meeting (EGM) unanimously approved the board's decision to issue a maximum of 41,791,743 series A shares, with a par value...

STOCKHOLM, Sweden, Sept. 28, 2005 (PRIMEZONE) -- Shareholders in Meda AB (publ), corporate ID 556427 2812 (hereafter the company), are hereby invited to attend an extraordinary general meeting...

STOCKHOLM, Sweden, Sept. 28, 2005 (PRIMEZONE) -- -- All relevant competition authorities approved acquisition of Viatris. -- Meda becomes one of the leading specialty pharma companies ...

STOCKHOLM, Sweden, Aug. 25, 2005 (PRIMEZONE) -- Meda sold its parallel trading operation, which leads to several accounting and technical consequences (because of IFRS 5) that affect comparability...

STOCKHOLM, Sweden, Aug. 8, 2005 (PRIMEZONE) -- Meda acquires the German pharmaceutical group Viatris and creates a leading European Specialty Pharma Company. -- Acquisition value of EUR 750m,...

STOCKHOLM, Sweden, June 27, 2005 (PRIMEZONE) -- Meda and Biophausia reached agreement regarding Meda's sale of its parallel trading operation. Biophausia is buying shares in two of Meda's...

STOCKHOLM, Sweden, May 02, 2005 (PRIMEZONE) -- On 2 May 2005, the AGM of Meda AB took these decisions to: Distribute company profits as per the board's proposal regarding a dividend of SEK...